Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10415 (
Bcl-2
)
33,771
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Strong evidence exists to support the tenet that activation of E2F transcription factors, via alterations in the p16-cyclin D-Rb pathway, is a key event in the malignant progression of most human malignant gliomas. The oncogenic ability of E2F has been related to the E2F-mediated up-regulation of several proteins that positively regulate cell proliferation. However, E2F may indirectly enhance proliferation by activating antiapoptotic molecules. In this work, we sought to ascertain whether
E2F-1
-mediated events involve the up-regulation of the antiapoptotic molecule
Bcl-2
. Western blot analyses showed up-regulation of
Bcl-2
but not of Bcl-x(L) by 24 h after the transfer of
E2F-1
. Northern blot studies showed that transfer of
E2F-1
also up-regulated
Bcl-2
RNA. In support of these findings and the concept that
E2F-1
has a direct effect in the induction of
Bcl-2
, we found a putative E2F binding site within the
Bcl-2
sequence. Subsequent gel-mobility shift and supershift experiments involving the CTCCGCGC site in the bcl-2 promoter showed that
E2F-1
bound
Bcl-2
. Transactivation experiments consistently showed that ectopic
E2F-1
activated responsive elements located in the -1448/-1441 region in the P1 promoter region of the bcl-2 gene. As expected, other members of the E2F family of transcription factors such as E2F-2 and E2F-4 also transactivated the bcl-2 promoter. Our results demonstrate that
E2F-1
modulates the expression of the antiapoptotic molecule
Bcl-2
and suggest that up-regulation of
Bcl-2
may favor the oncogenic role of
E2F-1
and other members of the E2F family of transcription factors.
...
PMID:Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2. 1155 37
Malignant transformation occurs in cells that overexpress c-Myc or that inappropriately activate
E2F-1
. Transformation occurs after the selection of cells that have acquired resistance to apoptosis that is triggered by these oncogenes, and a key mediator of this cell death process is the p53 tumor suppressor. In IL-3-dependent immortal 32D.3 myeloid cells the ARF/p53 apoptotic pathway is inactivated, as these cells fail to express ARF. Nonetheless, both c-Myc and
E2F-1
overexpression accelerated apoptosis when these cells were deprived of IL-3. Here we report that c-Myc or
E2F-1
overexpression suppresses
Bcl-2
protein and RNA levels, and that restoration of
Bcl-2
protein effectively blocks the accelerated apoptosis that occurs when c-Myc- or
E2F-1
-overexpressing cells are deprived of IL-3. Blocking p53 activity with mutant p53 did not abrogate
E2F-1
-induced suppression of
Bcl-2
. Analysis of immortal myeloid cells engineered to overexpress c-Myc and
E2F-1
DNA binding mutants revealed that DNA binding activity of these oncoproteins is required to suppress
Bcl-2
expression. These results suggest that the targeting of
Bcl-2
family members is an important mechanism of oncogene-induced apoptosis, and that this occurs independent of the ARF/p53 pathway.
...
PMID:Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. 1170 23
Although overexpression of
E2F-1
can induce apoptosis in a variety of tumor cell lines, the mechanisms by which
E2F-1
induces apoptosis remain ambiguous. In this study, we examine the ability of
E2F-1
to induce apoptosis in colon cancer and the molecular mechanisms underlying
E2F-1
-mediated apoptosis. HT-29 and SW-620 colon adenocarcinoma cells (both mutant p53) were treated by mock infection or adenoviral vectors Ad5CMV (empty vector), Ad5CMVLacZ (beta-galactosidase), and Ad5CMVE2F-1 (
E2F-1
) at multiplicity of infection of 100. Western blot analysis confirmed marked overexpression of
E2F-1
in both cell lines. By 5 days after infection,
E2F-1
overexpression resulted in >25-fold reduction in cell growth and >90% loss of cell viability in both cell lines. Cell cycle analysis of Ad-
E2F-1
-infected cells revealed an increase in G(2)/M and sub-G(1) populations. By in situ terminal deoxynucleotidyl transferase (Tdt)-mediated nick end labeling analysis, evidence of apoptosis was observed including internucleosomal DNA fragmentation and the formation of apoptotic bodies. In addition, caspase-3 and poly(ADP-ribose) polymerase apoptotic fragments were detected by 48 h after treatment with Ad-
E2F-1
. Of mechanistic importance, overexpression of
E2F-1
caused a G(2)/M arrest followed by increased levels of c-Myc and p14(ARF) proteins. Additionally, expression of the antiapoptotic
Bcl-2
family member Mcl-1 was down-regulated in
E2F-1
-overexpressing cells. In conclusion,
E2F-1
overexpression initiates apoptosis and suppresses growth in HT-29 and SW620 colon adenocarcinoma cells. Overexpression of
E2F-1
triggers apoptosis and is associated with up-regulation of c-Myc and p14(ARF) proteins and down-regulation of Mcl-1. Therefore,
E2F-1
is a potentially active gene therapy agent for the treatment of colon cancer.
...
PMID:E2F-1 up-regulates c-Myc and p14(ARF) and induces apoptosis in colon cancer cells. 1170 81
Pancreatic cancer is often resistant to conventional chemotherapy. In this study, we examined the role of adenovirus-mediated overexpression of
E2F-1
in inducing apoptosis and increasing the sensitivity of pancreatic cancer cells to chemotherapeutic agents. MIA PaCa-2 pancreatic head exocrine adenocarcinoma cells (mutant p53) were treated by mock infection or adenoviruses expressing beta-galactosidase or
E2F-1
(Ad-E2F-1) alone or in combination with sublethal concentrations of each chemotherapeutic drug. Cell growth and viability were assessed at selected time points. Apoptosis was evaluated by flow cytometry, characteristic changes in cell morphology and poly (ADP-ribose) polymerase (PARP) cleavage. Western blot analysis was used to examine the expression of
E2F-1
and
Bcl-2
family member proteins and PARP cleavage. Western blot analysis revealed marked overexpression of
E2F-1
at a multiplicity of infection (MOI) of 20 and 70. By 3 days after infection, Ad-
E2F-1
treatment at an MOI of 70 resulted in approximately a 20-fold reduction in cell growth and 60% reduction in cell viability as compared to mock-infected cells. Cell cycle analysis, PARP cleavage and changes in cell morphology supported apoptosis as the mechanism of cell death in response to
E2F-1
. In order to test the efficacy of treatment with a combination of gene therapy and chemotherapy, we utilized concentrations of Ad-
E2F-1
which reduced viability to 50% in combination with each chemotherapeutic agent. Cotreatment of the cells with
E2F-1
virus and roscovitine (ROS) or etoposide resulted in an additive effect on cell growth inhibition and induction of apoptosis. Interestingly, 5-fluorouracil did not cooperate with Ad-
E2F-1
in the mediation of tumor death or inhibition of cell growth. Immunoblotting for
Bcl-2
family members revealed no significant changes in the expression levels of
Bcl-2
, Bcl X(L), Bax or Bak following gene or 'chemogene' therapy with
E2F-1
. However, a Bax cleavage product was noted which was substantially increased by cotreatment with ROS or etoposide.
E2F-1
overexpression initiates apoptosis and suppresses growth in pancreatic MIA PaCa-2 cells in vitro.
E2F-1
-mediated apoptosis was not associated with significant changes in the expression of
Bcl-2
family member proteins in these pancreatic cancer cells. ROS and etoposide, when combined with
E2F-1
overexpression, induce apoptosis in an additive manner. This chemogene combination may provide a potentially useful therapeutic strategy for advanced pancreatic cancer.
...
PMID:E2F-1 gene therapy induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells. 1206 45
Gliomas are highly resistant to any kind of treatment. Multiple genetic abnormalities exist in gliomas indicating that effective gene therapy should be directed towards replacement of multiple rather than single genes. Bax is a protein of the
Bcl-2
family that promotes apoptosis and functions as a tumor suppressor gene. The E2F family of transcription factors plays a pivotal role in the regulation of cell-cycle and cell-death related genes in gliomas. We examined the therapeutic potential of the simultaneous transfer of Bax and E2F molecules (1, 2 or 4) to gliomas. We used first generation E1A-deleted adenoviral vectors to transduce the E2Fs and Bax cDNAs. The recombinant adenoviral vector encoding bax uses the inducible Cre-loxP system to transduce the protein expression. Western blot analysis and immunofluorescence assays demonstrated high level of expression of the exogenous proteins. Trypan blue cell viability assays and flow cytometric cell-cycle analysis demonstrated an additive effect of these molecules to induce cell death via apoptosis. Western blot analysis showed that the ectopic expression of
E2F-1
decreased the level of expression of Bax. These results indicate that
E2F-1
and Bax have an additive anti-glioma effect when expressed simultaneously at high levels. Our data also suggest that Bax is not involved in the
E2F-1
-mediated apoptosis.
...
PMID:Overexpression of E2F-1 leads to bax-independent cell death in human glioma cells. 1237 Jul 49
Apoptosis and necrosis represent two distinct types of cell death. Apoptosis possesses unique morphologic and biochemical features which distinguish this mechanism of programmed cell death from necrosis. Extrinsic apoptotic cell death is receptor-linked and initiates apoptosis by activating caspase 8. Intrinsic apoptotic cell death is mediated by the release of cytochrome c from mitochondrial and initiates apoptosis by activating caspase 3. Cancer chemotherapy utilizes apoptosis to eliminate tumor cells. Agents which bind to the minor groove of DNA, like camptothecin and Hoechst 33342, inhibit topoisomerase I, RNA polymerase II, DNA polymerase and initiate intrinsic apoptotic cell death. Hoechst 33342-induced apoptosis is associated with disruption of TATA box binding protein/TATA box complexes, replication protein A/single-stranded DNA complexes, topoisomerase I/DNA cleavable complexes and with an increased intracellular concentration of
E2F-1
transcription factor and nitric oxide concentration. Nitric oxide and transcription factor activation or respression also regulate the two apoptotic pathways. Some human diseases are associated with excess or deficient rates of apoptosis, and therapeutic strategies to regulate the rate of apoptosis include inhibition or activation of caspases, mRNA antisense to reduce anti-apoptotic factors like
Bcl-2
and survivin and recombinant TRAIL to activate pro-apoptotic receptors, DR4 and DR5.
...
PMID:Apoptosis: biochemical aspects and clinical implications. 1241 95
Redox imbalance due to oxidative stress or excessive antioxidant levels can alter apoptotic responses. Recently, antioxidants like N-acetylcysteine (NAC) were reported to inhibit H(2)O(2)-mediated necrotic cell death, although they were inactive against apoptosis induced by other agents like etoposide. NAC was also found to kill preferentially tumor cells compared to normal fibroblasts at 20-50mM, but these concentrations are lethal to normal splenocytes. We now demonstrate that 10mM NAC, a non-toxic concentration, can enhance the UV radiation-mediated apoptosis of human C8161 melanoma cells. Compared to treatment with UV radiation alone, combination treatment with NAC doubled the ratio of activated caspase-3 to pro-caspase-3 and produced greater fragmentation of the retinoblastoma protein and the E2F-4 transcription factor without affecting the
E2F-1
protein. These effects of joint NAC-UV radiation treatment were counteracted by the overexpression of the bcl-2 gene. To our knowledge, this report is the first to: (i) demonstrate a synergy between DNA-damaging agents, like UV radiation, and antioxidants, like NAC, and (ii) show that a
Bcl-2
-inhibitable E2F-4 fragmentation occurs concurrently with caspase-3 activation and apoptosis.
...
PMID:N-Acetylcysteine enhances UV-mediated caspase-3 activation, fragmentation of E2F-4, and apoptosis in human C8161 melanoma: inhibition by ectopic Bcl-2 expression. 1275 95
Transforming growth factor beta1 (TGF-beta1)-induced hepatocyte apoptosis is associated with activation of E2F transcription factors and p53 stabilization through Mdm-2, thus potentially modulating a number of target genes. In previous studies, we have shown that ursodeoxycholic acid (UDCA) prevents TGF-beta1-induced hepatocyte apoptosis by inhibiting the mitochondrial pathway of cell death. In this study we examined the role of p53 in the induction of apoptosis by TGF-beta1, and identified additional antiapoptosis targets for UDCA. Our data show a significant transcriptional activation of
E2F-1
in primary rat hepatocytes incubated with TGF-beta1, as well as a 5-fold increase in p53 and a 2-fold decrease in its inhibitor, Mdm-2 (p < 0.05). In addition, bax mRNA expression was significantly induced at 36 h (p < 0.01), resulting in increased levels of Bax protein. In contrast,
Bcl-2
transcript and protein levels were decreased at all time points (p < 0.01). Notably, UDCA inhibited
E2F-1
transcriptional activation, p53 stabilization and
Bcl-2
family expression (p < 0.05), in part, through a caspase-independent mechanism. Moreover, in the absence of TGF-beta1, UDCA prevented induction of p53 and Bax by overexpression of
E2F-1
and p53, respectively (p < 0.05). In addition, UDCA inhibited TGF-beta1-induced degradation of nuclear factor kappaB (NF-kappaB) and its inhibitor IkappaB (p < 0.05). In conclusion, these results demonstrate that UDCA inhibits
E2F-1
transcriptional activation of hepatocyte apoptosis, thus modulating p53 stabilization, NF-kappaB degradation, and expression of
Bcl-2
family members.
...
PMID:Ursodeoxycholic acid modulates E2F-1 and p53 expression through a caspase-independent mechanism in transforming growth factor beta1-induced apoptosis of rat hepatocytes. 1451 86
Neuronal apoptosis may be partly due to inappropriate control of the cell cycle. We used serum deprivation as stimulus and reduced potassium from 25 to 5mM (S/K deprivation), which induces apoptosis in cerebellar granule neurons (CGNs), to evaluate the direct correlation between re-entry in the cell cycle and apoptosis. Roscovitine (10 microM), an antitumoral drug that inhibits cyclin-dependent kinase 1 (cdk1), cdk2 and cdk5, showed a significant neuroprotective effect on CGNs deprived of S/K. S/K deprivation induced the expression of cell cycle proteins such as cyclin E, cyclin A, cdk2, cdk4 and
E2F-1
. It also caused CGNs to enter the S phase of the cell cycle, measured by a significant incorporation of BrdU (30% increase over control cells), which was reduced in the presence of roscovitine (10 microM). On the other hand, roscovitine modified the expression of cytochrome c (Cyt c),
Bcl-2
and Bax, which are involved in the apoptotic intrinsic pathway induced by S/K deprivation. We suggest that the antiapoptotic effects of roscovitine on CGNs are due to its anti-proliferative efficacy and to an action on the mitochondrial apoptotic mechanism.
...
PMID:Antiapoptotic effects of roscovitine in cerebellar granule cells deprived of serum and potassium: a cell cycle-related mechanism. 1460 88
Little is known about cell cycle regulation in hypoxic cells, despite its significance. We utilized an experimentally tractable model to study the proliferative responses of rat fibroblasts when rendered hypoxic (0.5% oxygen) or anoxic (<0.01% oxygen). Hypoxic cells underwent G1 arrest, whereas anoxic cells also demonstrated S-phase arrest due to suppression of DNA initiation. Upon reoxygenation, only those cells arrested in G1 were able to resume proliferation. The oncoprotein E1a induced p53-independent apoptosis in anoxic cells, which when suppressed by
Bcl-2
permitted proliferation despite anoxia. E1a expression led to marked increases in the transcription factor E2F, and overexpression of
E2F-1
allowed proliferation in hypoxic cells, although it had minimal effect on the anoxic suppression of DNA initiation. We thus demonstrate two distinct cell cycle responses to low oxygen and suggest that alterations that lead to increased E2F can overcome hypoxic G1 arrest but that additional alterations, promoted by E1a expression, are necessary for neoplastic cells to proliferate despite anoxia.
...
PMID:Anoxic fibroblasts activate a replication checkpoint that is bypassed by E1a. 1464 16
<< Previous
1
2
3
4
Next >>